From Euromed Article. We are going to capitalize b
Post# of 85520
Over the last year, EuroMed has been focused on forming strategic distribution relationships that will allow them to enter the European market. This represents a massive opportunity for the company to capitalize on markets where demand greatly exceeds supply for both CBD and THC products. EuroMed is currently looking at the exisiting opportunity in Germany, Poland, and Switzerland. This is an attractive aspect of the business and something that we will be monitoring,
A Growth Story to be Watching
With a limited number of companies being granted licenses from the Israeli government, EuroMed is in a great position to capitalize on a opportunity that is not saturated. If you look at how the early movers on the Canadian cannabis opportunity performed, you can see why we are excited about this advantage.
Israel has an attractive climate for cannabis cultivation and EuroMed had a management team that has diverse skill sets as well as a proven track record of success in a variety of sectors. We find this to be an important aspect of the story and are impressed with the way the team has been able to advance the opportunity.